Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gynecologic 3Breast 3Gastrointestinal 1

Conditions

Breast Neoplasms 34Ovarian Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Prostatic Neoplasms 2Neoplasms by Site 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Solid Tumors 2Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor, Adult 1Neoplasm Metastasis 1Melanoma 1HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

pembrolizumab 17Cisplatin 11Carboplatin 9Cyclophosphamide 8fludarabine 6Paclitaxel 6Nivolumab 6Bevacizumab 6aldesleukin 5Radiotherapy 5toripalimab 4tisotumab vedotin 4fludarabine phosphate 4Topotecan 4Interleukin-2 4Docetaxel 4Brachytherapy 4spartalizumab 3Ipilimumab 3Fulvestrant 3ferumoxtran-10 2enzalutamide 2durvalumab 2cemiplimab 2bemarituzumab 2balstilimab 2Trastuzumab 2Radiation 2Magnetic Resonance Spectroscopy 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Uterine Cervical Neoplasms × Fulvestrant × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡